Myasthenia Gravis: Clinical Features & Management

Overview

Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction. In most cases the autoantibodies target the postsynaptic acetylcholine receptor directly; a smaller subset instead targets MuSK (muscle-specific kinase), the protein that clusters those receptors at the junction. Either way, the density of functioning receptors on the muscle side of the synapse falls, and transmission becomes progressively less reliable with repeated use. A synapse that works fresh and fails once fatigued: that single mechanism explains every clinical feature of the disease, ocular and systemic alike.

The eye is disproportionately affected because the extraocular muscles and the levator palpebrae superioris are unusually vulnerable to junctional disease. They fire at high tonic rates to hold fixation and lid position all day, which exhausts a compromised synapse faster than an intermittently used limb muscle ever would. Roughly half of all MG patients present with a purely ocular manifestation, whether ptosis, diplopia, or both, and ptosis is the single most common initial presenting sign, reflecting early involvement of the levator. Some patients stay purely ocular for the rest of their disease course; others develop generalized weakness (bulbar, limb, respiratory) within the first two years. Every new ocular MG diagnosis therefore warrants monitoring for systemic progression rather than being treated as fixed and permanently localized.

Clinical Features

The defining clinical signature of MG at any site is fatigable weakness: strength that holds up after rest and deteriorates with sustained or repetitive use. In the eyes this produces diurnal variation, ptosis and diplopia that are mild or absent on waking and worsen through the day, especially after prolonged reading, driving, or any other sustained visual task. This one historical detail is among the most useful discriminators in the differential of acquired ptosis or diplopia. Almost no other cause of either symptom fluctuates on that particular clock.

Ocular motility involvement in MG can mimic almost any pattern: an isolated cranial nerve palsy, a bilateral gaze palsy, or even a picture resembling internuclear ophthalmoplegia. This is because the disease targets the neuromuscular junction itself rather than a specific nerve, nucleus, or tract. The resulting pattern of misalignment is non-anatomic and non-reproducible (different muscles affected to different degrees on different days), and that irregularity is itself a diagnostic clue: a genuine third or sixth nerve palsy produces a consistent, anatomically explicable pattern of weakness, while MG does not.

One finding is conspicuously absent in ocular MG: the pupil is spared. This matters because ocular MG is so often confused with compressive third nerve palsy. MG affects only the striated (skeletal) muscle of the levator and extraocular muscles, never the smooth muscle of the iris sphincter, so pupil size and light reactivity stay normal no matter how severe the ptosis or diplopia. A dilated, poorly reactive pupil accompanying ptosis should move the differential away from MG and toward a compressive lesion instead.

Diagnosis / Bedside Signs

Several inexpensive bedside maneuvers can demonstrate neuromuscular junction fatigability without any equipment beyond a clinician's hands and a penlight. They are frequently tested for exactly that reason: each one can be performed in an exam room in under a minute.

Cogan's Lid Twitch Sign

The patient looks down for roughly 10–15 seconds, fatiguing the already-weakened levator, then refixates rapidly to primary position. In a positive test, the upper lid briefly overshoots upward before settling back into its ptotic resting position: a transient "twitch" produced by the momentarily unfatigued fraction of the levator firing before it, too, gives out.

Peek Sign

The patient closes both eyes gently, not squeezing forcefully, and holds that position. In a positive peek sign, the orbicularis oculi (itself susceptible to the same fatigable weakness) cannot sustain closure. The lid fissures slowly separate over several seconds, revealing a strip of sclera, "peeking open," despite the patient's continued effort to keep the eyes shut.

Enhancement (Curtain) Sign

When one eyelid is severely ptotic and the other only mildly so, manually elevating the worse lid can cause the fellow, previously better lid to droop further. This happens because of Hering's law: both levators receive equal, yoked innervation, and central drive to the more affected lid had been increased to compensate. Lifting that lid manually removes the need for the extra drive; the reduced innervation is then reflected equally in the other lid, unmasking weakness that had been hidden.

The Mary Walker Effect

A more unusual, historically important finding: exercising an unrelated limb muscle to fatigue can transiently worsen ptosis or diplopia in a distant muscle group that was never itself exercised. This systemic spread of fatigue helped establish that MG is a humoral, circulating-antibody disease rather than a purely local one. The fatigue effect travels through the bloodstream, not just through local overuse of the affected muscle.

Beyond the bedside, ice-pack testing (cooling improves acetylcholinesterase kinetics and transiently improves ptosis), serologic testing for acetylcholine receptor and MuSK antibodies, and electrodiagnostic studies (repetitive nerve stimulation, single-fiber EMG) round out the formal diagnostic workup. In practice, though, the bedside maneuvers above are usually what raise the suspicion in the first place.

Management

Pyridostigmine, an acetylcholinesterase inhibitor, is the first-line symptomatic treatment. By slowing the breakdown of acetylcholine in the synaptic cleft, it prolongs the neurotransmitter's availability and improves the odds that enough of it reaches a reduced pool of receptors to trigger contraction. It is purely symptomatic: it does nothing to the underlying autoimmune process, and many patients with ocular MG find its effect on diplopia only partial.

When disease is inadequately controlled by pyridostigmine alone, or is generalized rather than purely ocular, immunosuppression is added. Corticosteroids are the traditional first choice, often with a steroid-sparing agent such as azathioprine or mycophenolate introduced to allow eventual steroid tapering. Thymectomy is a disease-modifying option, not merely symptomatic, in appropriate candidates, particularly generalized, acetylcholine receptor antibody-positive disease, given the strong association between MG and thymic pathology described above.

A myasthenic crisis, respiratory or bulbar weakness severe enough to threaten airway protection or require mechanical ventilation, is a medical emergency. It is treated with rapidly acting therapies rather than the slower-onset agents above: plasmapheresis or intravenous immunoglobulin (IVIG), both of which act within days to reduce circulating pathogenic antibody activity and buy time while slower immunosuppression takes hold.

Related Topics

Continue exploring Neuro-ophthalmology: